Quarterly report pursuant to Section 13 or 15(d)

Summary Significant Accounting Policies Parentheticals (Details)

v2.4.0.8
Summary Significant Accounting Policies Parentheticals (Details) (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Deferred Financing Costs    
Amortization of deferred financing costs related to convertible debt $ 4,835 $ 13,016
Impairment of Long-Lived Assets    
Company decided that the patents related to its former product ProAlgaZyme should be written off in the amount of   6,234
Research and Development    
Research Expenses - Salaries and equipment related expenses 0 30,000
Clinical Studies expenses - fees, charges and related expenses 1,306,000 680,000
Stock Based Compensation    
Compensation expenses recorded 125,983 360,103
Common shares from convertible debentures and related accrued interest 65,539,827 31,198,000
common shares from outstanding warrants 11,674,402 14,828,876
Advertising / Public Relations Costs    
Advertising and Public Relations costs are charged to operations when incurred 66,664 27,551
Concentrations of Credit Risk    
Company maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation ("FDIC") limit . $ 250,000 $ 0